Attorney Docket No.: 021756-002100US Client Reference No.: OID-2003-067-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SRIKANTH KARIMISETTY et al.

Application No.: Unassigned

Filed: Herewith

For: METHOD AND SYSTEM FOR CREATING QUERIES THAT OPERATE ON UNSTRUCTURED DATA STORED IN

A DATABASE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.97 and §1.98

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the U.S. patents and U.S. publications are not enclosed and copies of the publications are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the abovenoted Deposit Account.

Respectfully submitted,

William L. Shaffer Reg. No. 37,234

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834 Tel: 650-326-2400/Fax: 650-326-2422

WLS/ka 60096525 v1

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	Unassigned	
			SCLOSURE	Filing Date	Herewith	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Karimisetty, Srikanth	
				Art Unit	Unassigned	
	(use as many sh	eets a	s necessary)	Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number	021756-002100US	

	U.S. PATENT DOCUMENTS+						
		Document Number					
Examiner Initials*	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	AA	US-6,456,955 B1	09-24-2002	Andrews et al.			
	AB	US-6,584,459 B1	06-24-2003	Chang et al.			
	AC	US-2002-0023083 A1	02-21-2002	Durkalski			
	AD	US-2002-0107652 A1	08-08-2002	Andrews et al.			
	AE	US-2002-0143726 A1	10-03-2002	Planalp et al.			
	AF	US-2003-0069795 A1	04-10-2003	Boyd et al.	,		
	AG	US-2003-0069894 A1	04-10-2003	Cotter et al.			
	AH	US-2003-0088776 A1	05-08-2003	Lin et al.			
			<u> </u>		•		

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*		Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	T6	
		Country Code ³	Number ⁴	Kind Code ⁶ (if known)		Document	Figures Appear	┝
						2 22 22		
~			.•					

		· ·
Examiner Signature	Date Considered	

Substitute for form 1449B/PTO		Complete if Kn wn
INFORMATION DISCLOSU	Application Number	Unassigned
INFORMATION DISCLOSUI	riling Date	Herewith
STATEMENT BY APPLICAN	First Named Inventor	Karimisetty, Srikanth
	Art Unit	Unassigned
(use as many sheets as necessary)	Examiner Name	Unassigned
Sheet 2 of 2	Attorney Docket Number	021756-002100US

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2		
	AI	"FDA 21 CFR Part 11," Document Resources, http://www.documentresources.com/document/21cfrpart11.html, pp. 1-2, printed June 23, 2003.			
	AJ	"The Role of Technology Solutions in the Pharmaceutical and Biotechnology Industries' Search for 21 CFR Part 11 Compliance," Life Science CIO Forum, www.lifesciencesCIOforum.com, pp. 1-7 (2002).			
	AK	*21CFR Part 11 Opportunity or Challenge? With an Analysis of Oracle's OPM,* Life Science CIO Forum, www.lifesciencesClOforum.com, pp. 1-14 (2002).			
		,			
		•			
v					
		1			
			 		

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.